Long-term survival in multiple myeloma

Clinical Case Reports

Volumn 2, Issue 5, 2014, Pages 173-179

  João, Cristina ^a   Costa, Carlos ^a   Coelho, Inês ^a   Vergueiro, Maria João ^b   Ferreira, Mafalda ^a   da Silva, Maria Gomes ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b Centro de Investigacao e Criatividade em Informatica HFF   (Portugal)

Author keywords

Clinical characteristics in multiple myeloma; cytogenetics; multiple myeloma long survivors; toxicities

Indexed keywords

EID: 85019295390     PISSN: None     EISSN: 20500904     Source Type: Journal    
DOI: 10.1002/ccr3.76     Document Type: Article

References (35)

1. Siegel, R., D. Naishadham, and A. Jemal. 2013. Cancer statistics, 2012. CA Cancer J. Clin. 62:10–29.
2. Boyle, P., and J. Ferlay. 2005. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16:481–488.
3. Rachet, B., E. Mitry, A. Shah, N. Cooper, and M. P. Coleman. 2008. Survival from multiple myeloma in England and Wales up to 2001. Br. J. Cancer 99(Suppl. 1):S110–S112.
4. Kumar, S. K., S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, et al. 2008. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520.
5. Rajkumar, S. V., S. Jacobus, N. S. Callander, R. Fonseca, D. H. Vesole, M. E. Williams, et al. 2010. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11:29–37.
6. Sonneveld, P., I. G. H. Schmidt-Wolf, B. van der Holt, L. El Jarari, U. Bertsch, H. Salwender, et al. 2012. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J. Clin. Oncol. 30:2946–2955.
7. Kumar, S. K., A. Dispenzieri, M. A. Gertz, M. Q. Lacy, J. A. Lust, S. R. Hayman, et al. 2012. Continued improvement in survival in multiple myeloma and the impact of novel agents. ASH Annu. Meet. Abs. 120:3972.
8. Anguiano, A., S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, et al. 2009. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J. Clin. Oncol. 27:4197–4203.
9. Mikhael, J. R., D. Dingli, V. Roy, C. B. Reeder, F. K. Buadi, S. R. Hayman, et al. 2013. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88:360–376.
10. Avet-Loiseau, H., M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, et al. 2007. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myélome. Blood 109:3489–3495.
11. Stewart, A. K., and R. Fonseca. 2005. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J. Clin. Oncol. 23:6339–6344.
12. Munshi, N. C., K. C. Anderson, P. L. Bergsagel, J. Shaughnessy, A. Palumbo, B. Durie, et al. 2011. Consensus recommendations for risk stratification in multiple myeloma: report of the international myeloma workshop consensus panel 2. Blood 117:4696–4700.
13. Morgan, G. J., B. A. Walker, and F. E. Davies. 2012. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12:335–348.
14. Kuehl, W. M., and P. L. Bergsagel. 2012. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 122:3456–3463.
15. Palumbo, A., S. Bringhen, H. Ludwig, M. A. Dimopoulos, J. Bladé, M. V. Mateos, et al. 2011. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European myeloma network (EMN). Blood 118:4519–4529.
16. Greipp, P. R., J. San Miguel, B. G. M. Durie, J. J. Crowley, B. Barlogie, J. Bladé, et al. 2005. International staging system for multiple myeloma. J. Clin. Oncol. 23:3412–3420.
17. Kleber, M., G. Ihorst, B. Gross, B. Koch, H. Reinhardt, R. Wäsch, et al. 2013. Validation of the freiburg comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin. Lymphoma Myeloma leuk. 13:541–551.
18. Chakraborty, S., R. J. Hauke, N. Bonthu, and S. R. Tarantolo. 2012. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma – a SEER based study. Anticancer Res. 32:4507–4515.
19. Tsuchiya, J., H. Murakami, T. Kanoh, M. Kosaka, T. Sezaki, C. Mikuni, et al. 1994. Ten-year survival and prognostic factors in multiple myeloma. Br. J. Haematol. 87:832–834.
20. Finnish Leukaemia Group. 1999. Long-term survival in multiple myeloma: a Finnish leukaemia group study. Br. J. Haematol. 105:942–947.
21. Merchionne, F., P. Procaccio, and F. Dammacco. 2008. Long-term survival in multiple myeloma: a single-center experience. Clin. Exp. Med. 8:133–139.
22. Bryant, C., H. Suen, R. Brown, S. Yang, J. Favaloro, E. Aklilu, et al. 2013. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 3:e148.
23. Durie, B. G. M., J.-L. Harousseau, J. S. Miguel, J. Bladé, B. Barlogie, K. Anderson, et al. 2006. International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473.
24. 1998. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma trialists' collaborative group. J. Clin. Oncol. 16:3832–3842.
25. Egan, J. B., C.-X. Shi, W. Tembe, A. Christoforides, A. Kurdoglu, S. Sinari, et al. 2012. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 1201060–1066.
26. Fonseca, R., and J. Monge. 2013. Myeloma: classification and risk assessment. Semin. Oncol. 40:554–566.
27. Landgren, O., and G. J. Morgan. 2014. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin. Cancer Res. 20:804–813.
28. Avet-Loiseau, H., M. Attal, L. Campion, D. Caillot, C. Hulin, G. Marit, et al. 2012. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 30:1949–1952.
29. Rajkumar, S. V., G. Gahrton, and P. L. Bergsagel. 2011. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118:3205–3211.
30. Mikhael, J. R., D. Dingli, V. Roy, C. B. Reeder, F. K. Buadi, S. R. Hayman, et al. 2013. Pp. 360–376 in Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (MSMART) consensus guidelines. Mayo Clin. Proc. 88:360–376.
31. Zamagni, E., S. Bringhen, L. Pantani, A. Pezzi, B. A. Zannetti, P. Tacchetti, et al. 2013. Superior outcomes with bortezomib or thalidomide incorporated into autologous stem cell transplantation (ASCT) versus novel agent-based treatments for Elderly patients with newly diagnosed multiple myeloma (MM): a case-match comparison. Blood 122:3344.
32. Chubak, J., L. Tuzzio, C. Hsu, C. M. Alfano, B. A. Rabin, M. C. Hornbrook, et al. 2012. Providing care for cancer survivors in integrated health care delivery systems: practices, challenges, and research opportunities. J. Oncol. Pract. 8:184–189.
33. Campbell, M. K., I. Tessaro, M. Gellin, C. G. Valle, S. Golden, L. Kaye, et al. 2011. Adult cancer survivorship care: experiences from the LIVESTRONG centers of excellence network. J. Cancer Surviv. 5:271–282.
34. Othus, M., B. Barlogie, M. L. Leblanc, and J. J. Crowley. 2012. Cure models as a useful statistical tool for analyzing survival. Clin. Cancer Res. 18:3731–3736.
35. Félix, J., F. Aragão, J. M. Almeida, F. J. Calado, D. Ferreira, A. B. S. Parreira, et al. 2013. Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer 13:122.